Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia

Cancer Science

Volumn 99, Issue 5, 2008, Pages 967-972

  Kiyotani, Kazuma ^a   Mushiroda, Taisei ^a   Kubo, Michiaki ^a   Zembutsu, Hitoshi ^b   Sugiyama, Yuichi ^b   Nakamura, Yusuke ^a,b  

^a INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOCETAXEL; GENE PRODUCT; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; PROTEIN ABCC2; PROTEIN NR1I2; PROTEIN NR1I3; PROTEIN SLCO1B3; CARRIER PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; SLCO1B3 PROTEIN, HUMAN; TAXOID;

ANOREXIA; ARTICLE; BREAST CANCER; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG METABOLISM; DRUG TRANSPORT; ESOPHAGUS CANCER; GENETIC ASSOCIATION; GENOTYPE; HEREDITY; HUMAN; JAPAN; LEUKOPENIA; LUNG CANCER; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; VOMITING; CHEMICALLY INDUCED DISORDER; GENETIC POLYMORPHISM; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; GENOTYPE; HUMANS; LEUKOPENIA; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEUTROPENIA; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POLYMORPHISM, GENETIC; TAXOIDS;

EID: 43649103816     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00765.x     Document Type: Article

References (30)

1. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: A systematic review of clinical data. Lancet Oncol 2005; 6: 229-39.
2. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
3. Rougier P, Adenis A, Ducreux M et al. A phase II study: Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000; 36: 1016-25.
4. Ishimoto O, Sugawara S, Inoue A et al. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer. J Thorac Oncol 2006; 1: 979-83.
5. Evans WE, McLeod HL. Pharmacogenomics drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.
6. Baker SD, Li J, ten Tije AJ et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005; 77: 43-53.
7. Yamamoto N, Tamura T, Murakami H et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005; 23: 1061-9.
8. Marre F, Sanderink GJ, de Sousa G et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 1996; 56: 1296-302.
9. Sparreboom A, van Tellingen O, Scherrenburg EJ et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 1996; 24: 655-8.
10. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000; 6: 2598-603.
11. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-23.
12. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999; 274: 6043-6.
13. Burk O, Koch I, Raucy J et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 2004; 279: 38379-85.
14. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276: 14581-7.
15. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005; 116: 824-9.
16. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005; 4: 815-8.
17. Tanabe M, Ieiri I, Nagata N et al. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137-43.
18. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-99.
19. Itoda M, Saito Y, Soyama A et al. Polymorphisms in the ABCC2 (cMOAT/ MRP2) gene found in 72 established cell lines derived from Japanese individuals: An association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab Dispos 2002; 30: 363-4.
20. Letschert K, Keppler D, König J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004; 14: 441-52.
21. Hsieh KP, Lin YY, Cheng CL et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001; 29: 268-73.
22. Fukushima-Uesaka H, Saito Y, Watanabe H et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004; 23: 100.
23. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
24. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46: 471-7.
25. Sandusky GE, Mintze KS, Pratt SE, Dantzig AH. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 2002; 41: 65-74.
26. König J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family. Localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999; 1461: 377-94.
27. König J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000; 275: 23161-8.
28. Cui Y, König J, Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 2001; 60: 934-43.
29. Wada M, Toh S, Taniguchi K et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998; 7: 203-7.
30. Cui Y, König J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001; 276: 9626-30.